Artgen Biotech PJSC (MIC:ABIO) EV-to-Revenue : 5.00 (As of May. 25, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Artgen Biotech PJSC EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Artgen Biotech PJSC's enterprise value is ₽6,192 Mil. Artgen Biotech PJSC's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was ₽1,238 Mil. Therefore, Artgen Biotech PJSC's EV-to-Revenue for today is 5.00.

The historical rank and industry rank for Artgen Biotech PJSC's EV-to-Revenue or its related term are showing as below:

MIC:ABIO' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.34 Med: 3.06 Max: 9.96
Current: 5

During the past 13 years, the highest EV-to-Revenue of Artgen Biotech PJSC was 9.96. The lowest was 1.34. And the median was 3.06.

MIC:ABIO's EV-to-Revenue is ranked better than
62.46% of 1039 companies
in the Biotechnology industry
Industry Median: 8.18 vs MIC:ABIO: 5.00

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Artgen Biotech PJSC's stock price is ₽103.10. Artgen Biotech PJSC's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2023 was ₽13.65. Therefore, Artgen Biotech PJSC's PS Ratio for today is 7.55.

Artgen Biotech PJSC EV-to-Revenue Historical Data

The historical data trend for Artgen Biotech PJSC's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artgen Biotech PJSC EV-to-Revenue Chart

Artgen Biotech PJSC Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-Revenue

Get a 7-Day Free Trial

1.31

1.76

3.18

7.67

5.14

Artgen Biotech PJSC Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-Revenue	Get a 7-Day Free Trial															-	7.67	-	5.14	-

Competitive Comparison of Artgen Biotech PJSC's EV-to-Revenue

For the Biotechnology subindustry, Artgen Biotech PJSC's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Artgen Biotech PJSC's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artgen Biotech PJSC's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Artgen Biotech PJSC's EV-to-Revenue falls into.

Artgen Biotech PJSC EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Artgen Biotech PJSC's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	6192.044	/	1238.131
	=	5.00

Artgen Biotech PJSC's current Enterprise Value is ₽6,192 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Artgen Biotech PJSC's Revenue for the trailing twelve months (TTM) ended in Jun. 2023 was ₽1,238 Mil.

Artgen Biotech PJSC (MIC:ABIO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Artgen Biotech PJSC's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	103.10	/	13.651
	=	7.55

Artgen Biotech PJSC's share price for today is ₽103.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2023 was ₽13.65.

Artgen Biotech PJSC EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Artgen Biotech PJSC's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Artgen Biotech PJSC (MIC:ABIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artgen Biotech PJSC (MIC:ABIO) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Prospect of the 60th Anniversary, Moscow, RUS, 117036

Website

https://www.hsci.ru

Artgen Biotech PJSC formerly Human Stem Cells Institute PJSC is a biotechnology company. It is engaged in the drug discovery, research and development and marketing of proprietary products and services in the field of regenerative medicine, bio-insurance, medical genetics, including reproductive genetics, gene therapy, and biopharmaceutics. The company has developed Neovasculgen, which is a gene therapy drug for the treatment of Peripheral Arterial Disease, including Critical Limb Ischemia and also develops SPRS therapy which entails the use of autologous dermal fibroblasts to repair skin damage due to aging and other structural changes.